For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Tafamidis and Attruby represents a genuine change. These innovative therapies preserve https://attrcm230191.mdkblog.com/48300635/major-attr-cm-advance-the-drug-and-attruby-offer-hope